SensoGenic
Last updated: May 11, 2026
SensoGenic is a historically documented Israeli food-allergen biosensing startup that developed a handheld consumer analyzer for detecting allergenic proteins in food. Its current operating status is unclear because the former official domain no longer resolves to a company site and recent public evidence is limited.
Company Overview
SensoGenic was formed around a portable food-allergen biosensor intended to let allergic consumers test food before eating. European Commission CORDIS materials describe the product as a handheld digital diagnostic analyzer for consumers, originally focused on simultaneous detection of milk and eggs in relevant foods and concentrations. Later public coverage described a broader concept in which a food sample is applied to a cellulose strip, allergen-causing proteins bind to the strip, and a reader plus smartphone workflow reports the result.
The technology matters because food allergy management remains heavily dependent on labels, staff disclosure, kitchen procedures, and laboratory testing rather than real-time inspection at the point of consumption. If a disposable-strip reader can reliably detect clinically relevant protein residues across messy prepared-food matrices, it could reduce uncertainty in restaurants, schools, travel, catering, and shared kitchens. The hard technical problem is not the idea of immunoassay-based detection itself; it is achieving repeatable sensitivity, low false-negative rates, low cross-reactivity, reasonable sample preparation, and low consumable cost in foods with oils, sauces, heat-denatured proteins, and heterogeneous ingredients.
The company appears to have reached feasibility-stage validation rather than a clearly commercialized product. CORDIS records show a 2019 Horizon 2020 SME Instrument Phase 1 project coordinated by SENSOGENIC LTD in Rehovot with a EUR 50,000 EU contribution, and the reporting page says the company validated its proof of concept and used the project to conduct market research and discussions with food and beverage manufacturers and allergy specialists. A 2019 article reported beta testing and an expected 2022 market launch, but there is no strong public evidence that this launch occurred. The former official website, sensogenic.com, is referenced by CORDIS and startup directories, but current web checks show it redirects to unrelated content, so the database should not treat it as an active canonical site.
Competitive dynamics are difficult because SensoGenic sat between consumer electronics, diagnostics, and industrial food testing. Consumer-facing devices such as Allergy Amulet and the former Nima model frame the user experience expectations, while established food-safety testing vendors, lateral-flow assays, ELISA kits, and accredited laboratories provide substitutes for professional users. SensoGenic's claimed edge was a potentially lower-cost, multi-allergen disposable strip workflow, but that advantage would require independent analytical validation, regulatory/claims discipline, manufacturing reliability, and enough consumer trust to support repeated use.
For Claw & Talon, SensoGenic is best treated as a biosensing diligence reference, not a priority dual-use company. Portable protein detection could be adjacent to field screening, supply-chain assurance, and institutional food-safety inspection, including on military bases or deployed food-service settings. However, the public record does not show defense customers, biosecurity positioning, hazardous-agent detection, or an active product roadmap beyond consumer food allergy management. The most important current diligence question is whether SensoGenic still operates as an independent company or whether the asset is dormant, since the historical CEO and co-founder Alon Yasovsky is publicly reported in 2025 as having moved into a vice president of R&D role at ParaZero.
Strategic Fit Assessment
This should not be treated as a current strategic priority signal. The underlying biosensing idea is technically relevant, and the company had credible 2019 feasibility validation through the EU SME Instrument, but the lack of an active official web presence, unclear commercialization after the projected 2022 launch, and weak defense/security fit make the record unsuitable for an strategically relevant dual-use thesis.
Strategic Value to U.S.-Israel Alliance
Strategic value is limited and mostly indirect. The asset of interest is portable, low-cost protein detection know-how that could inform broader field biosensing or food-supply assurance work, but the documented company focus was consumer allergy management rather than national-security missions, force protection, bio-threat detection, or defense logistics platforms.
Key Technologies
- Cellulose-based allergen protein capture strips
- Portable handheld biosensor reader hardware
- Antibody or affinity-reagent allergen recognition
- Smartphone-connected result display and workflow
- Low-ppm food-protein detection concept
- Disposable multi-allergen sample pads
- Consumer-oriented food-sample preparation workflow
Use Cases & Applications
- Pre-meal allergen screening by food-allergic consumers
- Restaurant dish checks before serving high-risk diners
- Catering and event food-allergy verification
- School and childcare cafeteria spot checks
- Shared-kitchen cross-contact screening
- Travel and hospitality food-safety checks
- Institutional food-service quality assurance in hospitals or military facilities
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Open-web verification is limited. Readers should confirm current status, customers, funding, and product claims before relying on this profile.
Verification note: public information is limited; this entry is retained for ecosystem-mapping purposes and should not be relied on without further confirmation.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- cordis.europa.eu Public source used for profile verification.
- cordis.europa.eu Public source used for profile verification.
- bridgesforpeace.com Public source used for profile verification.
- f6s.com Public source used for profile verification.
- Crunchbase profile Public source used for profile verification.
- investing.com Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on May 11, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
SensoGenic may matter as a Semiconductors & DeepTech Hardware entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies SensoGenic's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Is there a credible national-security or public-sector use case, or is the company primarily a commercial technology asset?
- What export-control, supply-chain, manufacturing, or classified-market constraints could affect U.S. and allied adoption?
- Is the company a live venture opportunity, a mature strategic reference, an acquired asset, or primarily a market-mapping entry?
Related sector
See the Semiconductors & DeepTech Hardware sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.